



Broadview Ventures | 265 Franklin Street, Suite 1902 | Boston MA, 02110 | broadviewventures.org | 617.459.4686

2021 PORTFOLIO MOMENTUM

- The Broadview pipeline remains robust with more than 400 investment opportunities considered in 2021
- Our portfolio companies raised \$227M in co-investments, follow-on financings, and grants
- This year, across our portfolio, our co-investors included 683 Capital, Acorn BioVentures, Affinity Asset Advisors, Ajax Health, Altium Capital, Aperture Venture Partners, Apollo Health Ventures, Atlantic Bridge, Chardan Healthcare Investments, Cleveland Clinic Ventures, Epidarex Capital, F-Prime, GV, Hatteras Venture Partners, Humbolt Fund, Ikarian Capital, Innogest Capital, JMCR, Lilly Asia Ventures, Population Health Ventures, RTW Investments, Santé Ventures, Schroder Adveq, Sio Capital Management, SOSV, Southern Ocean Capital, and Surveyor Capital
- The technologies of Broadview's portfolio companies have touched the lives of more than 190,000 patients to date

NEW INVESTMENTS

- XII Medical—Minimally-invasive technology to address obstructive sleep apnea (OSA)
- RapidPulse—Novel aspiration system to treat acute ischemic stroke
- Comanche BioPharma—Novel siRNA therapeutic for the treatment of preeclampsia




Longview Ventures, a \$100M fund dedicated to making follow-on investments in select Broadview portfolio companies, made the following investment:

 Renovacor—Longview participated in a \$30M PIPE as part of Renovacor's merger with Chardan Healthcare Acquisition 2. Renovacor, which is developing adenoassociated virus (AAV) based gene therapies for a rare, familial form of dilated cardiomyopathy, raised a total of \$95M and is trading on the New York Stock Exchange (NYSE) under the ticker symbol RCOR.


TALENT

David Prim joined the Broadview investment team as a Senior Associate. Most recently, David was a Senior Associate at Locust Walk, where he led engagements for biopharma and medtech clients guiding corporate development strategy and supporting sell-side, buy-side, and financing deal execution. David earned a PhD in Biomedical Engineering from the University of South Carolina, where his research focused on vascular grafting.

BROADVIEW AND LONGVIEW'S INVESTMENTS ARE LEVERAGED 15.2X BY ADDITIONAL FUNDING SOURCES



BROADVIEW INVESTMENTS BY INDICATION



INVESTMENTS THROUGH 2021

* Exited

Company	Technology/Therapy	Founders/Management
2021 ————		
XII Medical	minimally-invasive technology to address obstructive sleep apnea (OSA)	Garrett Schwab, Anthony Caparso
RapidPulse	novel aspiration system to treat acute ischemic stroke	Sean McBrayer, David Gill, Carlos Rivera
Comanche BioPharma	novel siRNA therapeutic for the treatment of preeclampsia	T. Scott Johnson, Mike Young, Craig Mello
2020 ————		
Antag Therapeutics	GIPR antagonist for obesity in T2DM population	Alexander Sparre-Ulrich, Mette Rosenkilde, Jens Juul Ho
Basking Biosciences	reversible anti-vWF aptamer for acute ischemic stroke	Richard Shea, Shahid Nimjee, Bruce Sullenger
HAYA Therapeutics	ncRNA-targeting antifibrotic therapeutics for heart failure	Samir Ounzain, Daniel Blessing
2019 ————		
Alleviant Medical	atrial shunt for the treatment of heart failure	Jacob Kriegel, Adam Berman
Renovacor	gene therapy for a rare, familial form of dilated cardiomyopathy	Maggie Cook, Arthur Feldman
CroíValve	percutaneously implanted device for tricuspid regurgitation	Lucy O'Keeffe, Martin Quinn
2018 ————		
AtaCor Medical	leadless extravascular pacing and defibrillation system	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Cantum Pharma	P2Y14 antagonists to ameliorate and prevent sterile inflammation	Sylvie Breton, Glenn Batchelder
2017 ————		
Nido	device for epicardial ablation of ventricular tachycardia	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
//ellitus	novel biomarker for the screening and diagnosis of gestational diabetes	Jose Halperin, Michael Chorev, John Tagliamonte
Adient*	bioresorbable IVC filter for prevention of pulmonary embolism	Mitch Eggers, Joseph Steele
ectorious/	direct left atrial pressure sensor	Oren Goldshtein, Eyal Orion
EP Sciences	novel defibrillation waveform to reduce pain associated with ICD therapies	Ron Berger, Howard Levin
2016 ————		
ineHeart	fully implantable, miniaturized circulatory support device for HF	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois
Gila Therapeutics	PYY agonist for management and treatment of obesity	Tom Vasicek, Scott Schorer
Aeromics	small molecule for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson
015		
Pulmokine*	small molecule for pulmonary artery hypertension	Larry Zisman, Shreefal Mehta
yra Therapeutics	bioresorbable platform for multiple indications	Bob Langer, George Whitesides, Maria Palasis
Epirium	mitochondrial biogenesis platform technology	George Schreiner, Sundeep Dugar, Russell Cox
014 —		
Z Biotech	peptide therapeutic for stroke	Berislav Zlokovic, Kent Pryor, Joseph Romano
schemia Care	gene-based diagnostic for stroke	Jeff June
Acesion Pharma	small molecule therapeutic for AF	Ulrik Sørensen, Morten Grunnet, Jørgen Søberg Peterse
Aria CV	device for pulmonary hypertension	John Scandurra, Karl Vollmers, Dan Gladney
Alia CV	device for pullitoriary hypertension	John Scanduna, Ran voiliners, Dan Glauney

INVESTMENTS THROUGH 2021

Company Technology/Therapy

* Exited

Zumbro Discovery	peptide therapeutic for treatment of resistant hypertension	John Burnett, Horng Chen
BioKier	small molecule anti-diabetic treatment	George Szewczyk, Roger Nolan
Remedy*	small molecule for the treatment of central nervous system edema	Sven Jacobson
GI Windows*	non-surgical approach to gastric bypass	Chris Thompson, Marvin Ryou
2012 ————		
/GS	external support for saphenous vein grafts in CABG	Eyal Orion
nfoBionic	cloud-based remote arrhythmia monitoring	Jeremy Ruskin, Stuart Long
Herantis	VEG-F based gene therapy for lymphedema	Craig Cook
DecImmune	MAb for treatment of post MI and I/R injury	Christopher Mirabelli, Walter Newman
2011 ————		
Cardialen	implantable cardioversion for the treatment of AF	Igor Efimov, Jeff Peters
NuPulse	counterpulsation device for the treatment of HF	Valluvan Jeevanandam, Douglas Altschuler
Aggamin	novel preeclampsia treatment	Ravi Thadhani, Paul Kussie, Ananth Kamuranch
Provasculon*	peptide therapeutics for treatment of MI and I/R injury	Rich Lee, Roger Kitterman
Apama*	novel ablation system for treatment of AF	Amr Salahieh
2010 ————		
Allosteros	CaMKII inhibitors for HF and AF	Howard Schulman, Mark Anderson
ntravascular Imaging	NIRF device for intracoronary artery imaging	Farouc Jaffer, Vasilis Ntziachristos
Capricor*	allogeneic stem cell therapy after MI	Eduardo and Linda Marbán
CellAegis	remote ischemic conditioning for MI	Andrew Redington, Chris Calderone
2009		
CardiAQ Valve*	transcatheter mitral valve	Brent Ratz, Arshad Quadri, Rob Michiels
/entriNova	gene therapy for regeneration of cardiac tissue	Hina Chaudhry
miRagen*	microRNAs for cardiovascular and oncology indications	Bruce Booth, Mike Bristow, Eric Olson

Founders/Management



BROADVIEW VENTURES TEAM

MANAGEMENT

Christopher Colecchi Managing Director

Maria Berkman, MD
Christopher de Souza, PhD
Daniel Gottlieb
Benjamin Kreitman
Hewmun Lau
David Milan, MD
Nichole Neal
Tom Needham
David Prim, PhD
Sunny Varshney, MD

ADVISORS

Annabel Chen-Tournoux, MD Teo Dagi, MD Marc Semigran, MD Viviany Taqueti, MD, MPH

STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD Thomas Hughes, PhD Constantino Iadecola, MD Jerry Karabelas, PhD Martín Landaluce Joseph Loscalzo, MD, PhD Eric Rose, MD David Tancredi, MD, PhD Hugh Watkins, MD, PhD



LONGVIEW VENTURES INVESTMENT ADVISORY COMMITTEE

EXTERNAL MEMBERS

Terry McGuire Chris Mirabelli, PhD Eric Rose, MD

LEDUCQ MEMBERS

Martín Landaluce David Milan, MD David Tancredi, MD, PhD